- The P-III INBUILD trial involves assessing of OFEV vs PBO in patients with chronic fibrosing interstitial lung disease (ILDs) with signs of progression for 52 wks.
- P-III INBUILD study results: met its 1EPs, slowed lung function decline by 57%, adjusted annual rate of decline in FVC @52 wks. (-80.8 mL/year vs -187.8 mL/year). Ofev showed consistent effect on lung function decline in patients with UIP like fibrotic pattern and those with other fibrotic patterns on HRCT, consistent safety profile as found in IPF and SSc-ILD patients
- Ofev (nintedanib) is a tyrosine kinase inhibitor approved in 70+ countries including the US, EU and Japan for the treatment of patients living with idiopathic pulmonary fibrosis (IPF)
Click here to read full press release/ article | Ref: Boehringer Ingelheim | Image: Twitter